Highlights from

EAN 2019

European Academy of Neurology

Oslo 29 June - 2 July 2019

Galcanezumab reduces healthcare resource utilisation

Findings from the phase 3 REGAIN study revealed that galcanezumab treatment significantly reduced migraine-specific healthcare resource utilisation as well as migraine headache days (MHD) that require acute medication use in patients with chronic migraine [1].

In the phase 3 study REGAIN, patients with chronic migraine were randomised to placebo (n=558), galcanezumab 120 mg (n=278), or galcanezumab 240 mg (n=277). A 3-month double-blind period was followed by a 9-month open-label extension (OLE) phase with flexible dosing. Changes in mean migraine-specific healthcare resource utilisation across baseline, double-blind, and OLE phases (per 100 patient-years) were calculated for healthcare professional visits, emergency room visits, admissions to hospital, and overnight hospital stays. Mean reductions from baseline across time in number of MHD/month with acute medication use were significant in each of the 3 groups (see Table).

Table: Change in mean migraine headache days per month across different stages of REGAIN [1]

EAN MCR 2019 D1-Digitaal-10b

The majority of patients in the REGAIN study shifted from chronic to episodic migraine status [2]. After 3 months, a greater proportion of galcanezumab-treated patients shifted from chronic to episodic status (30.9%) versus placebo-treated patients (19.7%). Across the 12-month period, 65.1% of galcanezumab-treated patients shifted to episodic status for ≥3 consecutive months. The authors concluded that long-term treatment with galcanezumab may lead to substantial reductions in disability and economic burden.

  1. Joshi S, et al. EAN 2019, EPO2137.
  2. Detke H, et al. EAN 2019, EPO1134.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.